BARDA is opening TechWatch again to all threat areas; including COVID-19 technologies! Submit your TechWatch Request now for the opportunity for the U.S. government experts to discuss your product, technology or capabilities and explore potential partnering opportunities.
990+
COVID-19 TechWatch Meetings Held To-Date
COVID-19 CoronaWatch requests from every state in the USA
30+
Countries - CoronaWatch Meeting Requests from Around the Globe
*Reflects COVID-19 requests submitted 1/30/20-11/4/21. All COVID-19 requests submitted after 11/4/2021 are reflected as TechWatch requests.
1,580+
TechWatch Market Research Meetings with innovative companies
TechWatch requests from every state in the USA
70+
Countries - TechWatch Meeting Requests from Around the Globe
The U.S. government (USG) provides a portal as a single point of entry for the submission of meeting requests from interested stakeholders with promising MCM products, technologies, and capabilities.
The USG seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products, technologies, and capabilities that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products, technologies, or capabilities relevant to respond to public health emergencies are sought.
We ask for a brief description of your product technology, or capability, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note while we use information you present as market research; submission is no guarantee of a meeting or funding and your submission will be shared with our teams involved in medical countermeasure research and development. Only USG officials are invited to join TechWatch meetings and are bound by law to maintain the confidentiality of what is presented and discussed.
Typically, TechWatch meeting submissions are reviewed within 30 days of submission. If your product, technology, or capability aligns with our program priorities it is likely we will contact you to set up a TechWatch meeting within an additional 30 days. Please note due to the complexities and priorities related to the pandemic slight delays in timing may result.
SELECT A STEP TO LEARN MORE
Before You Submit:
Submit
Submit basic product information or view/update existing submissions. Upon successful submission, you will receive a confirmation email with a Tracking ID (e.g.: BDR-TW-2022-00001).
Evaluate & Prioritize*
We will evaluate your request and route it to the most appropriate resource within the federal government.
*See BARDA TechWatch Evaluation Areas for BARDA’s assessment areas.
Notification
We will schedule a targeted or broad meeting.
OR
A meeting is not scheduled, but your technology is retained for future reference.
Before You Submit:
Explore the TechWatch submission threats and areas BARDA is actively assessing.
| Threat | Category |
|---|---|
| Acute Radiation Syndrome | Rad/Nuc |
| Anthrax (Bacillus anthracis) | Biological |
| Antimicrobial Resistance / Antibiotic Susceptibility Tests | Biological |
| Biodosimetry Self-Assessment Tools | Rad/Nuc |
| Biotoxins | Chemical |
| Blister Agents/Vesicants | Chemical |
| Blood Agents (cyanide, H2S) | Chemical |
| Blood Products and Blood-derived Products | Rad/Nuc |
| Botulism (Clostridium botulinum toxin) | Biological |
| Brucellosis (Brucella species) | Biological |
| Burn/Blast Injury | Rad/Nuc |
| Choking/Lung/Pulmonary Agents | Chemical |
| Chronic Effects of Radiation Exposure | Rad/Nuc |
| Coronaviruses (e.g., SARS, MERS, COVID-19) | Biological |
| Epidemic/Pandemic Influenza | Biological |
| Glanders (Burkholderia mallei) | Biological |
| Incapacitating Agents | Chemical |
| Influenza | Biological |
| Internal Contamination (radiation/decorporation of isotopes) | Rad/Nuc |
| Meliodosis (Burkholderia pseudomallei) | Biological |
| Nerve Agents | Chemical |
| Patient decontamination | Chemical |
| Plague (Yersinia pestis) | Biological |
| Smallpox (variola major) | Biological |
| Trauma therapeutics | Rad/Nuc |
| Tularemia (Francisella tularensis) | Biological |
| Viral hemorrhagic fevers (filoviruses, arenaviruses, other viruses in order Bunyavirales, flaviviruses) | Biological |
| Viruses, other RNA (flaviviruses, alphaviruses, picornaviruses, paramyxoviruses, Bunyavirales order) | Biological |
| Program | Category |
|---|---|
| BARDA Ventures | DRIVe |
| Beyond the Needle | DRIVe |
| Bringing Laboratory Testing to the Home | DRIVe |
| Digital Health Tools for Pandemic Preparedness | DRIVe |
| DRIVe Start efforts/challenges | DRIVe |
| Host Based Diagnostics | DRIVe |
| Host Based Therapeutics | DRIVe |
| Infection Severity and Solving Sepsis | DRIVe |
| ReDIRECT | DRIVe |
| Threat | Category |
|---|---|
| Caustics (Acids) | Chemical |
| Epsilon Toxin of Clostridium perfringens | Biological |
| Food Safety Threats (e.g., Salmonella species, Escherichia coli O157:H7, Shigella) | Biological |
| Long-Acting Anticoagulants | Chemical |
| Metals | Chemical |
| Organic Solvents | Chemical |
| Psittacosis (Chlamydia psittaci) | Biological |
| Q Fever (Coxiella burnetti) | Biological |
| Ricin Toxin from Ricinus communis (castor beans) | Biological |
| Riot Control Agents/Tear Gas | Chemical |
| Staphylococcal enterotoxin B | Biological |
| Surface decontamination (biological or chemical) | Biological |
| Toxic Alcohols | Chemical |
| Typhus fever (Rickettsia prowazekii) | Biological |
| Water Safety Threats (e.g., Vibrio cholerae, Cryptosporidium parvum) | Biological |
| Zika virus disease | Biological |
| Program | Category |
|---|---|
| ENACT | DRIVe |
| Home Dx | DRIVe |
| Immune Chip | DRIVe |
| Next-Generation Sequencing (NGS) | DRIVe |
| Rapidly Deployable Capabilities | DRIVe |
Note: TechWatch submissions are not considered for potential funding
Note: Entities with a White Paper or proposal currently under review for any ASPR solicitation are not eligible to schedule a TechWatch meeting related to that submission. If you have concerns regaring your eligibility, please raise them with our TechWatch team as soon as possible.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) manages our nation’s investments in chemical, biological, radiological, and nuclear (CBRN) defense equipment and medical countermeasures. JPEO-CBRND leads, manages, and directs the acquisition, fielding and sustainment of CBRN sensors, protective equipment, medical countermeasures, specialized equipment for U.S. Special Forces, integration and information management systems, and defense enabling biotechnologies.
Submissions to JETT are designed to begin the conversation, they a not considered submissions for potential funding. If you have an idea, a technology, or a capability that, either directly or indirectly, could help us protect the Joint Force, we’d like to engage to learn more!
Planning tools for stakeholders for therapeutic, vaccine, and device candidates
EXPLORE THESE TOOLS
